Sri Ramachandra Journal of Health Sciences,
Год журнала:
2025,
Номер
4, С. 44 - 52
Опубликована: Март 1, 2025
Background
Artificial
intelligence
(AI)
is
a
boon
to
the
human
race
that
offers
transformative
potential
in
medical
care
system,
revolutionizing
well-being.
Over
past
five
decades,
AI
has
evolved
significantly
deep
learning
and
machine
(ML).
subfields
work
together
provide
for
various
applications.
ML
self-learning
system
can
improve
its
performance
through
training
experiences.
Utilizing
artificial
neural
networks
mimics
brain
functions,
while
computer
vision
involves
computers
extracting
information
from
images
or
videos.
The
application
of
deployed
across
diverse
fields,
including
cardiology,
dermatology,
ophthalmology,
oncology,
enhancing
diagnostic
procedures
treatment
outcomes.
Objective
This
review
aims
explore
current
trends
healthcare,
evaluate
impact
different
identify
future
prospects
AI-driven
innovations
personalized
medicine
beyond.
Method
A
comprehensive
literature
analysis
was
undertaken
using
prominent
databases
such
as
“PubMed,”
“Scopus,”
“Google
Scholar.”
Results
found
impacted
multiple
areas
healthcare.
In
diagnostics,
applications
have
improved
accuracy
efficiency,
particularly
fields
cardiology
oncology.
Overall,
holds
promise
success
will
depend
on
addressing
challenges
continuing
advance
both
technology
implementation
practices.
medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 21, 2025
Abstract
Anti-NMDAR1
autoantibodies
can
bind
NMDA
receptors
to
suppress
glutamate
excitotoxicity
in
the
brain.
Low
titers
of
blood
circulating
natural
anti-NMDAR1
were
reported
∼10%
general
human
population.
We
developed
a
new
method
more
accurately
quantify
these
low
autoantibodies.
After
quantifying
plasma
324
age–
and
sex-matched
subjects
(163
healthy
controls;
161
Alzheimer’s
disease
(AD)
patients),
I
found
that
AD
patients
carrying
higher
levels
have
significantly
(p
value:
0.003)
scores
Mini-Mental
State
Examination
(MMSE
score:
23.5)
than
lower
21.4).
No
significant
differences
MMSE
however
between
controls
with
either
or
autoantibodies,
indicating
little
harmful
effect
Consistently,
superior
cognitive
performances
comparison
These
data
suggest
may
neuroprotective
effects
against
decline
patients.
Receptors,
Год журнала:
2025,
Номер
4(1), С. 2 - 2
Опубликована: Янв. 26, 2025
Glucagon-like
peptide-1
receptor
agonists
(GLP-1RAs),
including
dulaglutide,
liraglutide,
semaglutide,
and
exenatide,
are
effective
treatments
for
type
2
diabetes
mellitus
(T2DM)
obesity.
These
agents
mimic
the
action
of
endogenous
incretin
glucagon-like
(GLP-1)
by
enhancing
insulin
secretion,
inhibiting
glucagon
release,
promoting
weight
loss
through
appetite
suppression.
GLP-1RAs
have
recently
been
suggested
to
neuroprotective
effects,
suggesting
their
potential
as
treatment
neurodegenerative
disorders,
such
Alzheimer’s
disease
(AD).
AD
T2DM
share
several
common
pathophysiological
mechanisms,
resistance,
chronic
inflammation,
oxidative
stress,
mitochondrial
dysfunction.
shared
mechanisms
suggest
that
therapeutic
targeting
metabolic
dysfunction
may
also
be
beneficial
conditions.
Preclinical
studies
on
in
models,
both
vitro
vivo,
demonstrated
promising
reductions
amyloid-beta
accumulation,
decreased
tau
hyperphosphorylation,
improved
synaptic
plasticity,
enhanced
neuronal
survival.
Despite
encouraging
results
from
preclinical
challenges
need
addressed
before
can
widely
used
treatment.
Ongoing
clinical
trials
investigating
cognitive
benefits
patients,
aiming
establish
role
a
option
AD.
This
review
aimed
examine
current
literature
GLP-1
Neurology International,
Год журнала:
2025,
Номер
17(2), С. 26 - 26
Опубликована: Фев. 7, 2025
Alzheimer’s
and
Parkinson’s
are
the
most
common
neurodegenerative
diseases
(NDDs).
The
development
of
aberrant
protein
aggregates
progressive
permanent
loss
neurons
major
characteristic
features
these
disorders.
Although
precise
mechanisms
causing
disease
(AD)
(PD)
still
unknown,
there
is
a
wealth
evidence
suggesting
that
misfolded
proteins,
accumulation
dysfunction
neuroreceptors
mitochondria,
dysregulation
enzymes,
release
neurotransmitters
significantly
influence
pathophysiology
diseases.
There
no
effective
protective
medicine
or
therapy
available
even
with
availability
numerous
medications.
an
urgent
need
to
create
new
powerful
bioactive
compounds
since
number
people
NDDs
rising
globally.
Heterocyclic
have
consistently
played
pivotal
role
in
drug
discovery
due
their
exceptional
pharmaceutical
properties.
Many
clinically
approved
drugs,
such
as
galantamine
hydrobromide,
donepezil
hydrochloride,
memantine
opicapone,
feature
heterocyclic
cores.
As
therapeutic
potential,
heterocycles
intriguing
research
topic
for
drugs
PD
AD.
This
review
aims
provide
current
insights
into
potential
use
targeting
diverse
targets
manage
potentially
treat
patients
AD
PD.
Alzheimer s & Dementia,
Год журнала:
2025,
Номер
21(3)
Опубликована: Март 1, 2025
Abstract
INTRODUCTION
Polypharmacy
is
common
among
older
adults
and
people
with
dementia.
Multi‐medication
therapy
poses
risks
of
harm
but
also
targets
comorbidities
risk
factors
associated
dementia,
offering
therapeutic
potential.
METHODS
We
evaluated
the
effects
two
polypharmacy
regimens
monotherapies
on
male
female
App
NL‐G‐F
knock‐in
mice.
assessed
functional,
emotional,
cognitive
outcomes;amyloid
pathology;
serum
metabolomics
profiles.
RESULTS
A
combination
metoprolol,
simvastatin,
aspirin,
paracetamol,
citalopram
improved
memory,
reduced
amyloid
burden
neuroinflammation,
modulated
AD‐associated
metabolomic
signatures
in
mice,
negligible
Substituting
cardiovascular
drugs
impacted
emotional
domains
worsened
predominantly
In
males,
could
not
explain
effects,
suggesting
drug
synergy,
whereas
certain
monotherapy
were
lost
when
combined.
DISCUSSION
This
study
uncovers
sex‐specific
an
AD
model,
identifying
mechanisms
biomarkers
that
can
guide
gender‐specific
use
medicines
dementia
prevention
management.
Highlights
Two
combinations
show
pathology
Metoprolol+simvastatin+aspirin+paracetamol+citalopram
improves
memory
Replacing
metoprolol
simvastatin
enalapril
atorvastatin
eliminates
benefits
mice
impairs
Selected
produce
only
partially
outcomes
combinations.
Metabolomic
pathways
indicate
possible
for
evaluating
effectiveness
safety
personalized
therapies
aging
